- About About
-
Medical
Medical
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
-
-
Colorado drug investigator to Utah: Beware of medical marijuana
By Kristen Moulton Salt Lake Tribune
Legalizing medical marijuana would open the door to a host of problems, including abuse by children and deaths from psychotic reactions, a Colorado drug-law enforcer warned Utah lawmakers Wednesday.
Jim Gerhardt, vice president of the Colorado Drug Investigators Association, provided the Health and Human Services Interim Committee with a litany of woes Utah's neighboring state has experienced since legalizing medical marijuana.
He showed pictures of people who have committed suicide after using pot or who have been killed by high family members. He played a chilling videotape interview of a cavalier teenager who had killed a motorcyclist with his own car while stoned. A house blew up because of improper electrical use for a grow operation, he said.
"This becomes a tangled mess for law enforcement," said Gerhardt, one of four speakers to address the committee in a three-hour hearing. Three were medical researchers.
It was the committee's second long hearing on the topic of medical marijuana this summer.
Saratoga Springs Republican Sen. Mark Madsen is championing legislation that would legalize medical marijuana.
His bill last session narrowly died in the Senate. Sen. Evan Vickers, R-Cedar City, said he, too, has a bill in the works.
Madsen called Gerhardt's testimony "very emotional and scary," but questioned how it applies to Utah.
"Have you read the bill and how it deals with everything you've highlighted here?" he asked Gerhardt. The Colorado drug investigator conceded he had not read the measure.
One witness invited by Madsen to testify by video link was Jahan Marcu, director of research and development at Green Standard Diagnostics and senior science adviser at Americans for Safe Access.
Marcu cited a study that found some cancer-fighting properties in pot and another that determined teens were unhurt by marijuana use.
Importantly, he said, deaths from opioids (prescription painkillers) have declined in Colorado since medical marijuana was allowed there.
Two Utah researchers said more research needs to be done on medical marijuana, including on dosages, interaction with other drugs, and which compounds might help with what conditions.
Lynn Webster, vice president of scientific affairs at PRA Health Sciences and a prominent pain physician, said Utah could become a laboratory for the research medical marijuana desperately needs.
It could perhaps reduce the use of addictive opioids, he said.
"The public has gone further than the science has, and there is a potentially significant benefit from measured and managed risk," Webster said. "We should be doing something to move forward. There is too much harm from opioids and too much suffering from chronic pain."
Annette Fleckenstein of the University of Utah sketched the basic biological effects of marijuana on the brain and urged lawmakers to read the National Institute on Drug Abuse's materials on it.
While there are many anecdotes about therapeutic benefits, "It really is important that we can begin to do these studies," said Fleckenstein, assistant dean for Foundational Sciences and deputy director of the Utah Addiction Center at the U.
Share